| pubmed-article:20126826 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C0683949 | lld:lifeskim |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:20126826 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20126826 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20126826 | pubmed:dateCreated | 2010-5-27 | lld:pubmed |
| pubmed-article:20126826 | pubmed:abstractText | Comparison of the binding affinity to a CD30-positive Hodgkin lymphoma (HL) cell line and biodistribution in HL bearing mice of new anti-CD30 radioimmunoconjugates (RICs) of varying structure and labelling nuclides. | lld:pubmed |
| pubmed-article:20126826 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20126826 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20126826 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20126826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20126826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20126826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20126826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20126826 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20126826 | pubmed:issn | 0029-5566 | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:FischerTT | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:HansenHH | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:SchichaHH | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:EngertAA | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:SchnellRR | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:TawadrosSS | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:SchomäckerKK | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:StaabDD | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:KobeCC | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:Pogge von... | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:DietleinMarku... | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:ZimmermannsBB | lld:pubmed |
| pubmed-article:20126826 | pubmed:author | pubmed-author:BörnerS MSM | lld:pubmed |
| pubmed-article:20126826 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20126826 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:20126826 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20126826 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20126826 | pubmed:pagination | 97-105 | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:meshHeading | pubmed-meshheading:20126826... | lld:pubmed |
| pubmed-article:20126826 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20126826 | pubmed:articleTitle | Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies. | lld:pubmed |
| pubmed-article:20126826 | pubmed:affiliation | Department for Nuclear Medicine, University of Cologne, 50937 Cologne, Germany. markus.dietlein@uni-koeln.de | lld:pubmed |
| pubmed-article:20126826 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20126826 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
